Immuno-Oncology

The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

Latest News

"Persistent" Subset of Tumor Mutations May Predict Immunotherapy Response
"Persistent" Subset of Tumor Mutations May Predict Immunotherapy Response

January 26th 2023

A study published in Nature Medicine found that certain tumor mutations are more persistent and may predict immunotherapy responses more reliably than overall tumor mutational burden.

Axi-cel Shows Improved Quality-Adjusted Survival Versus Standard of Care in LBCL
Axi-cel Shows Improved Quality-Adjusted Survival Versus Standard of Care in LBCL

January 19th 2023

From Lymphomas to Myeloma, Bispecific Antibodies Make a Big Splash at ASH
From Lymphomas to Myeloma, Bispecific Antibodies Make a Big Splash at ASH

January 14th 2023

Immune Profiling Study Offers Potential New Patient-Stratification Tools in Glioblastoma
Immune Profiling Study Offers Potential New Patient-Stratification Tools in Glioblastoma

January 10th 2023

How CAR T Therapies Stack Up Against Standard of Care for LBCL Across Lines of Treatment, Cost Perspectives
How CAR T Therapies Stack Up Against Standard of Care for LBCL Across Lines of Treatment, Cost Perspectives

January 7th 2023

Video Interviews
Podcasts

More News

© 2023 MJH Life Sciences
AJMC®
All rights reserved.